CV Therapeutics Ranexa Benefit Over Norvasc Will Be Focus Of Additional Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Refractory angina trial designed under a special protocol assessment with FDA will begin in the third quarter. The company predicts a "broad restricted label" based on the study, which follows recommendations made by FDA's Cardio-Renal Drugs Advisory Committee.
You may also be interested in...
Ranexa MERLIN Trial Could Support First-Line Angina, Acute Coronary Syndrome Indications
CV Therapeutics says 5,500-patient Ranexa outcomes trial in ACS patients expected to begin in fourth quarter under a special protocol assessment with FDA. An absence of a trend towards death or arrhythmia would be sufficient for first-line chronic angina claim, firm says.
Ranexa MERLIN Trial Could Support First-Line Angina, Acute Coronary Syndrome Indications
CV Therapeutics says 5,500-patient Ranexa outcomes trial in ACS patients expected to begin in fourth quarter under a special protocol assessment with FDA. An absence of a trend towards death or arrhythmia would be sufficient for first-line chronic angina claim, firm says.
Ranexa May Launch In 2006; CV Therapeutics And FDA Discussing New Study
The company expects to obtain a special protocol assessment for the trial, which will likely focus on a restricted angina population. After approval, CVT expects to expand the label through additional studies.